Lion Street Advisors LLC cut its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 7.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,943 shares of the exchange traded fund’s stock after selling 300 shares during the quarter. Lion Street Advisors LLC’s holdings in SPDR S&P Biotech ETF were worth $390,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of XBI. Fifth Third Bancorp boosted its stake in SPDR S&P Biotech ETF by 3.4% in the 2nd quarter. Fifth Third Bancorp now owns 118,303 shares of the exchange traded fund’s stock worth $10,968,000 after purchasing an additional 3,922 shares in the last quarter. RFG Advisory LLC bought a new stake in shares of SPDR S&P Biotech ETF during the first quarter valued at approximately $219,000. Avantax Advisory Services Inc. raised its holdings in SPDR S&P Biotech ETF by 17.2% in the 1st quarter. Avantax Advisory Services Inc. now owns 9,619 shares of the exchange traded fund’s stock worth $913,000 after acquiring an additional 1,415 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in SPDR S&P Biotech ETF by 28.8% in the 1st quarter. Banque Cantonale Vaudoise now owns 14,199 shares of the exchange traded fund’s stock valued at $1,347,000 after acquiring an additional 3,179 shares in the last quarter. Finally, PFG Investments LLC boosted its stake in SPDR S&P Biotech ETF by 9.2% during the 2nd quarter. PFG Investments LLC now owns 24,844 shares of the exchange traded fund’s stock valued at $2,303,000 after purchasing an additional 2,097 shares during the last quarter.
SPDR S&P Biotech ETF Price Performance
XBI stock opened at $98.68 on Friday. The stock has a market capitalization of $7.52 billion, a P/E ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 1-year low of $63.80 and a 1-year high of $103.52. The business has a fifty day moving average price of $98.54 and a 200-day moving average price of $94.17.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Dividend Capture Strategy: What You Need to Know
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- The Basics of Support and Resistance
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.